INSMED INCORPORATED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 26 USD | -0.31% |
|
+1.60% | -16.10% |
Presenter SpeechBryan Dunn (Executives)Good morning, everyone, and welcome to The Future of Ra...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Insmed Incorporated is a global biopharmaceutical company. The Company's first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is used for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its pipeline includes clinical-stage programs, brensocatib and TPIP, as well as other early-stage research programs. Brensocatib is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1), which is developing for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases, including chronic rhinosinusitis without nasal polyps (CRSsNP). TPIP is an inhaled formulation of the treprostinil prodrug treprostinil palmitil, which offers a differentiated product profile for pulmonary hypertension associated with interstitial lung disease (PH-ILD) and pulmonary arterial hypertension (PAH).
Calendar
2024-05-08
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
26
USD
Average target price
44.07
USD
Spread / Average Target
+69.49%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -16.10% | 3.87B | |
| +2.93% | 106B | |
| +7.02% | 23.47B | |
| -14.60% | 21.9B | |
| -7.05% | 18.77B | |
| -38.55% | 17.85B | |
| -8.83% | 16.78B | |
| +5.51% | 14.41B | |
| +37.49% | 12.86B | |
| +329.39% | 8.78B |
- Stock Market
- Equities
- INSM Stock
- News Insmed Incorporated
- Transcript : Insmed Incorporated - Shareholder/Analyst Call